Global Idiopathic Pulmonary Fibrosis Market to 2030 – By Drug Type, Distribution Channel and Region | News

0

DUBLIN, March 30, 2022 /PRNewswire/ — The “Idiopathic Pulmonary Fibrosis Market by Drug Type and Distribution Channel: Global Opportunities Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.comit’s offer.

The Global Idiopathic Pulmonary Fibrosis Market has been valued at $3,126.08 million in 2020, and should reach $6,169.37 million by 2030, registering a CAGR of 7.0% from 2021 to 2030.

Idiopathic pulmonary fibrosis is a chronic lung disease or condition in which the tissues of the lungs become thick and stiff over time. Due to the thickening of lung tissue, the brain and other organs cannot receive optimal oxygen. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen through the bloodstream effectively. The disease usually affects people between the ages of 50 and 70. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung disease (also known as PID), which describes lung diseases that involve inflammation or scarring in the lungs.

The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, staccato cough. Many affected individuals also experience loss of appetite and gradual weight loss. Some people with idiopathic pulmonary fibrosis develop enlarged, rounded tips of the fingers and toes (digital clubbing) as a result of lack of oxygen.

Major factors driving the growth of the global idiopathic pulmonary fibrosis market include increasing prevalence of fibrotic disease and increasing geriatric population. Furthermore, increasing demand for cost-effective drugs and introduction of advanced treatment options are propelling the growth of the market. However, the unavailability of suitable disease treatment options is limiting the market growth.

The global idiopathic pulmonary fibrosis market is segmented on the basis of drug type, distribution channel, and region. Based on drug type, the market is split into pirfenidone and nintedanib. Based on the distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online providers. Geographically, it is analyzed through North America, Europe, Asia Pacificand LAMEA)

Key Benefits

  • The study provides an in-depth analysis of the global Idiopathic Pulmonary Fibrosis market along with current trends and future estimations to elucidate impending investment pockets.
  • A comprehensive analysis of factors driving and restraining market growth is provided in the report.
  • A comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable stakeholders to capitalize on existing market opportunities.
  • In-depth analysis of key industry segments helps in understanding Idiopathic Pulmonary Fibrosis products and end users used worldwide.
  • Major market players and their strategies have been analyzed to understand the competitive outlook of the market.

Main topics covered:

CHAPTER 1 INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Main results of the study

2.1.1. CXO point of view

CHAPTER 3: MARKET OVERVIEW

3.1. Definition and scope of the market

3.2. Main findings

3.2.1. The best investment pockets

3.3. Positioning of the best player, 2020

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining power of suppliers

3.4.2. The bargaining power of buyers

3.4.3. The threat of new entrants

3.4.4. The threat of substitutes

3.4.5. Intensity of competitive rivalry

3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in the incidence of cancer worldwide

3.5.1.2. Rise of the global geriatric population

3.5.1.3. Increase in smoking

3.5.2. Detention

3.5.2.1. Lack of awareness and proper treatment.

3.5.3. Opportunities

3.5.3.1. Increase in the number of drugs in development

3.5.3.2. Growth opportunities in emerging markets

3.5.4. Impact analyzes

3.6. Analysis of the impact of COVID-19 on the market

3.7. Pipeline analytics

CHAPTER 4: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Pirfenidone

4.2.1. Key Market Trends, Growth Drivers and Opportunities

4.2.2. Market size and forecast

4.2.3. Market analysis, by country

4.3. Nintedanib

4.3.1. Key Market Trends, Growth Drivers and Opportunities

4.3.2. Market size and forecast

4.3.3. Market analysis, by country

CHAPTER 5: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL

5.1. Overview

5.1.1. Market size and forecast, by distribution channel

5.2. Hospital pharmacies

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

5.3. Retail pharmacy

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

5.4. Online pharmacy

5.4.1. Market size and forecast, by region

5.4.2. Market analysis, by country

CHAPTER 6: IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION

CHAPTER 7: COMPANY PROFILES

7.1. AstraZeneca Plc.

7.1.1. Company presentation

7.1.2. Company Overview

7.1.3. Operating business areas

7.1.4. Product portfolio

7.1.5. Company performance

7.1.6. Key strategic moves and developments

7.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH

7.2.1. Company presentation

7.2.2. Company Overview

7.2.3. Operating business areas

7.2.4. Product portfolio

7.2.5. Company performance

7.3. Bristol-Myers Squibb Company

7.3.1. Company presentation

7.3.2. Company Overview

7.3.3. Operating business areas

7.3.4. Product portfolio

7.3.5. Company performance

7.4. Biogene, Inc.

7.4.1. Company presentation

7.4.2. Company Overview

7.4.3. Operating business areas

7.4.4. Product portfolio

7.4.5. Company performance

7.5. FibroGen, Inc.

7.5.1. Company presentation

7.5.2. Company Overview

7.5.3. Operating business areas

7.5.4. Product portfolio

7.5.5. Company performance

7.6. F. Hoffmann-La Roche SA

7.6.1. Company presentation

7.6.2. Company Overview

7.6.3. Operating business areas

7.6.4. Product portfolio

7.6.5. Company performance

7.6.6. Key strategic moves and developments

7.7. GNI Group Ltd.

7.7.1. Company presentation

7.7.2. Company Overview

7.7.3. Operating business areas

7.7.4. Product portfolio

7.7.5. Company performance

7.8. Galapagos NV.

7.8.1. Company presentation

7.8.2. Company Overview

7.8.3. Operating business areas

7.8.4. Product portfolio

7.8.5. Company performance

7.9. Therapeutic Mission

7.9.1. Company presentation

7.9.2. Company Overview

7.9.3. Operating business areas

7.9.4. Product portfolio

7.10. Shionogi & Co Ltd

7.10.1. Company presentation

7.10.2. Company Overview

7.10.3. Operating business areas

7.10.4. Product portfolio

7.10.5. Company performance

For more information on this report, visit https://www.researchandmarkets.com/r/sk1lar

Media Contact:

Research and Markets

Laura Woodsenior

[email protected]

For EST office hours, call +1-917-300-0470

For USA/CAN call toll free +1-800-526-8630

For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904

Fax (outside the US): +353-1-481-1716

Show original content:https://www.prnewswire.com/news-releases/global-idiopathic-pulmon-fibrosis-market-to-2030—by-drug-type-distribution-channel-and-region-301513941.html

SOURCE Research and Markets

Share.

Comments are closed.